With reference to Gubra's A/S (CPSE:GUBRA) announcement on March 28, 2025 regarding the satisfaction of the regulatory condition for a license agreement to develop GUB014295, ...
GUBamy was well tolerated with adverse events being predominantly GI related, mild and consistent with data from the SAD study. Doses of 1 mg and 2 mg GUBamy administered once-weekly ...
GUBamy, AbbVie-licensed amylin drug from Gubra, shows 7.8% weight loss in Phase 1 trial, vs 2% weight gain with placebo after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback